Loading cancer entity…
Subtype
CI-CAN-00002836HNSCC · SCCHNExplore in graph →
Clinical trials
1,589 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (247)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04999800 | Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1 | unknown | Phase 2 | 20 | Shi YuankaiUNKNOWN | 1 | Aug 11, 2021 | clinicaltrials |
| NCT03450967 | Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCC | unknown | Phase 2 | 31 | Samsung Medical CenterOTHER | 1 | Aug 10, 2021 | clinicaltrials |
| NCT04464967 |
| Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers |
| withdrawn |
| Phase 1 / Phase 2 |
| 0 |
| NKGen Biotech, Inc.INDUSTRY |
| 0 |
| May 12, 2021 |
| clinicaltrials |
| NCT04882462 | Sintilimab and Nimotuzumab Combined With Chemotherapy for the Treatment of R/M HNSCC.(Carpp-1) | unknown | Phase 2 | 100 | The First Affiliated Hospital of Soochow UniversityOTHER | 0 | May 12, 2021 | clinicaltrials |
| NCT02762513 | Expansion Trial for Axitinib In Head And Neck Cancer | completed | Phase 2 | 29 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 5, 2021 | clinicaltrials |
| NCT03134846 | Image Guided Surgery for Margin Assessment of Head and Neck Cancer Using Cetuximab-IRDye800CW cONjugate(ICON) | unknown | Phase 1 / Phase 2 | 79 | University Medical Center GroningenOTHER | 1 | May 3, 2021 | clinicaltrials |
| NCT04861467 | Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma | unknown | Phase 2 | 155 | Chinese Academy of Medical SciencesOTHER | 1 | Apr 27, 2021 | clinicaltrials |
| NCT04523883 | Concurrent Immunotherapy With Postoperative Radiotherapy in Intermediate/High Risk HNSCC Patients Unfit for Cisplatin: The IMPORT Study (IMPORT)(IMPORT) | unknown | Phase 2 | 316 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Apr 15, 2021 | clinicaltrials |
| NCT03194373 | Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | completed | Phase 2 | 21 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 12, 2021 | clinicaltrials |
| NCT00896181 | Phase 2 Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC) | completed | Phase 2 | 26 | Stanford UniversityOTHER | 1 | Apr 6, 2021 | clinicaltrials |
| NCT04826679 | Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC | unknown | Phase 2 | 53 | Sun Yat-sen UniversityOTHER | 1 | Apr 1, 2021 | clinicaltrials |
| NCT03771820 | Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen | unknown | Phase 2 | 136 | NanoCarrier Co., Ltd.INDUSTRY | 8 | Mar 17, 2021 | clinicaltrials |
| NCT02054442 | A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and Neck(COMMENCE) | unknown | Phase 1 / Phase 2 | 52 | Radboud University Medical CenterOTHER | 1 | Mar 12, 2021 | clinicaltrials |
| NCT00084682 | Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2021 | clinicaltrials |
| NCT04440917 | Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma(IMplus) | unknown | Phase 2 | 32 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Feb 2, 2021 | clinicaltrials |
| NCT03908372 | Optimized Treatment Strategies for Early and Medium Stage Nasopharyngeal Carcinoma | unknown | Phase 2 / Phase 3 | 120 | Chinese Academy of Medical SciencesOTHER | 1 | Jan 29, 2021 | clinicaltrials |
| NCT01414426 | Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions | completed | Phase 2 | 20 | University of ChicagoOTHER | 1 | Jan 14, 2021 | clinicaltrials |
| NCT01602315 | A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | terminated | Phase 1 / Phase 2 | 179 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 29, 2020 | clinicaltrials |
| NCT00210470 | A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer | completed | Phase 2 | 27 | Brooklyn ImmunoTherapeutics, LLCINDUSTRY | 0 | Dec 11, 2020 | clinicaltrials |
| NCT01689194 | Efficacy Study of Genexol-PM and Cisplatin in Locally Advanced Head and Neck Cancer | completed | Phase 2 | 53 | Seoul National University HospitalOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT03655444 | Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy | terminated | Phase 1 / Phase 2 | 6 | Washington University School of MedicineOTHER | 1 | Dec 3, 2020 | clinicaltrials |
| NCT01386632 | Study of DCA (Dichloroacetate) in Combination With Cisplatin and Definitive Radiation in Head and Neck Carcinoma | completed | Phase 2 | 50 | Sanford HealthOTHER | 1 | Oct 27, 2020 | clinicaltrials |
| NCT00736944 | Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer | completed | Phase 2 | 30 | Washington University School of MedicineOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT04220749 | Radiotherapy vs. Trans-Oral Surgery for HPV-Negative Oropharyngeal Squamous Cell Carcinoma | recruiting | Phase 2 | 68 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Sep 4, 2020 | clinicaltrials |
| NCT04093115 | Study of CX1106 in Patients With Advanced Head and Neck Squamous Cell Carcinoma(HNSCC) | withdrawn | Phase 2 | 0 | Beijing Konruns Pharmaceutical Co., Ltd.INDUSTRY | 0 | Sep 3, 2020 | clinicaltrials |
| NCT04525066 | Phonosurgical Augmentation After Laser Resection of Early Glottic Carcinoma | completed | Phase 2 | 39 | Ayhman Al AfifOTHER | 0 | Aug 25, 2020 | clinicaltrials |
| NCT02124707 | Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN | completed | Phase 2 | 14 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 12, 2020 | clinicaltrials |
| NCT03874741 | SCT200 Plus Platinum-based Chemotherapy in Head and Neck Squamous Cell Carcinoma | unknown | Phase 2 | 25 | Sinocelltech Ltd.INDUSTRY | 1 | May 27, 2020 | clinicaltrials |
| NCT04399785 | Phase II Study for Combination of Camrelizumab and SBRT in the First-line Treatment for R/M HNSCC | unknown | Phase 2 | 34 | Xingchen PengOTHER | 1 | May 22, 2020 | clinicaltrials |
| NCT01192815 | Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck | terminated | Phase 2 | 2 | Case Comprehensive Cancer CenterOTHER | 1 | May 12, 2020 | clinicaltrials |
| NCT03433027 | A Study of BB-401 in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | completed | Phase 2 | 16 | Benitec Biopharma, Inc.INDUSTRY | 2 | Apr 15, 2020 | clinicaltrials |
| NCT00957853 | Preoperative Treatment With Cetuximab and/or IMC-A12 | completed | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT01044433 | Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck | completed | Phase 2 | 44 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT02452424 | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | terminated | Phase 1 / Phase 2 | 78 | Daiichi SankyoINDUSTRY | 1 | Mar 5, 2020 | clinicaltrials |
| NCT04296747 | Toripalimab in Combination With Chemotherapy as Induced Chemotherapy for Localized Hypopharyngeal Cancer | unknown | Phase 2 | 100 | Peking Union Medical College HospitalOTHER | 0 | Mar 5, 2020 | clinicaltrials |
| NCT01697800 | A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract | completed | Phase 2 | 40 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 28, 2020 | clinicaltrials |
| NCT01469429 | Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. | completed | Phase 1 / Phase 2 | 70 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 20, 2020 | clinicaltrials |
| NCT02882308 | Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck.(OPHELIA) | completed | Phase 2 | 41 | Hellenic Cooperative Oncology GroupOTHER | 1 | Feb 7, 2020 | clinicaltrials |
| NCT03463161 | Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy(ORKA) | terminated | Phase 2 | 2 | University of ChicagoOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT01998542 | Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck(HNC) | completed | Phase 2 | 12 | Mirror Biologics, Inc.INDUSTRY | 1 | Jan 23, 2020 | clinicaltrials |
| NCT04222543 | Imaging of Tumour Microenvironment in Patients With Oropharyngeal Head and Neck Squamous Cell Carcinoma Using RGD PET/CT Imaging(PIVOT) | unknown | Phase 2 | 20 | Radboud University Medical CenterOTHER | 1 | Jan 10, 2020 | clinicaltrials |
| NCT04146181 | Safety and Efficacy of SCT-I10A in Head and Neck Squamous Cell Carcinoma | unknown | Phase 2 | 103 | Sinocelltech Ltd.INDUSTRY | 1 | Dec 12, 2019 | clinicaltrials |
| NCT02335918 | A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 175 | Celldex TherapeuticsINDUSTRY | 1 | Dec 9, 2019 | clinicaltrials |
| NCT04164238 | Neoadjuvant Anti-PD-1 Antibody (Toripalimab) or Combined With Chemotherapy in HNSCC Patients | unknown | Phase 2 | 90 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Nov 15, 2019 | clinicaltrials |
| NCT01774760 | Reproducibility of Intratumor Distribution of 18F-EF5 in Head and Neck Cancer | completed | Phase 2 | 10 | Turku University HospitalOTHER_GOV | 1 | Oct 4, 2019 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT02794077 | Cyclophosphamide for Nasopharyngeal Carcinoma | completed | Phase 2 | 56 | The University of Hong KongOTHER | 0 | Oct 2, 2019 | clinicaltrials |
| NCT00408252 | Efficacy of SU 011248 in Head And Neck Carcinoma | terminated | Phase 2 | 54 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 2 | Sep 19, 2019 | clinicaltrials |
| NCT02339558 | Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 3 | Sep 13, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Aug 11, 2021source: clinicaltrials